跳至主要内容

Single B Cell antibody discovery technology

 Medicilon can provide Single B Cell antibody discovery service, which contains Single B Cell Sorting, Single B cell Ig Gene Transcription, Amplification, and Sequencing. The principle of single B cell antibody discovery technology is that each B cell contains only a pair of functional heavy chain and light chain and each B cell has the characteristic of producing only one specific antibody.

Monoclonal antibodies (mAbs) are important tools for many diagnostic applications and research.  In addition, monoclonal antibodies have become an ideal therapeutic product for many diseases, and have been well used in the treatment of cancer, autoimmune diseases and infectious diseases.   A number of techniques are used to generate monoclonal antibodies for research and therapeutic purposes.  Single B cell screening is a newly developed technique for rapid preparation of mab in recent years. The principle is that each B cell only contains a pair of functional heavy and light chains, and each B cell only produces aspecific antibody characteristic, which can be directly amplified from a single B cell to obtain mab. This method has the advantages of fast speed, high throughput, and natural pairing of variable regions of antibody weight and light chains. It is one of the new and efficient methods for antibody discovery.

  • Process of Single B Cell Antibody Production

    The process of Single B Cell Antibody discovery.webp

  • The Concept of Single B Cell Antibody discovery technology

    The principle of single B cell antibody discovery technology is that each B cell contains only a pair of functional heavy chain and light chain and each B cell has the characteristic of producing only one specific antibody.  Therefore, the antibody coding sequence can be amplified directly from a single B cell to obtain a monoclonal antibody.
  • Single B Cell Sorting

    Depending on the research application, single B cells can be isolated randomly or antigen-selectively from peripheral blood or lymphoid tissues (bone marrow, spleen).  For the isolation of B cells, current single B cell sorting technology include flow cytometry, magnetic bead cell sorting, micromanipulation, laser microdissection, and microfluidic sorting.  Fluorescence activated Cell Sorting (FACS) is a mature and effective single cell sorting technology.

    FACS.webp

  • Single B cell Ig Gene Transcription, Amplification, and Sequencing

    Construction of complementary DNA (cDNA) from a single B cell provides an efficient method for simultaneous analysis of expressed IgH and IgL genes.  Typically, single B-cell cDNA synthesis is performed in equipment used for cell deposition and cell lysis (96-well plates, nanowell chips, etc.), which ensures easily handling of large numbers of samples and minimizes the risk of cross-contamination.  Full-length Ig variable region gene transcripts were amplified by nested PCR, and RT-PCR products were used as samples for the first round of PCR for further reactions.

    Regardless of the Ig variable region gene amplification strategy used, the transcriptional information of the Ig variable region genes encoding antibody-specific single B-cells was subsequently sequenced.  Then using various databases such as NCBI's IgBLAST and IMGT, the rearranged V, D and J gene segments can be easily identified and analyzed for mutations, insertions and deletions.

  • Case Study: Nectin-4 Mouse Serum Titer

    Case Study: Nectin-4 Mouse Serum Titer.webp

    Case Study: Nectin-4 (4-1) Sorting Single B Cell

    Case Study: Nectin-4 (4-1) Sorting Single B Cell.webp

    Case Study: Nectin-4 (4-1) Sequencing (Top20)

    Case Study: Nectin-4 (4-1) Sequencing (Top20).webp

    Case Study: Nectin-4 (4-6) Sorting Single B Cell

     Case Study: Nectin-4 (4-6) Sorting Single B Cell.webp

    Case Study: Nectin-4 (4-6) Sequencing (Top20)

    Case Study: Nectin-4 (4-6) Sequencing (Top20).webp

评论

此博客中的热门博文

The Launch Meeting was Held by Medicilon and DAC Biotech of the Contract Research on ADC Preclinical Study

  Chuansha, Shanghai, Nov. 8th, 2019 — Medicilon held the launch meeting with Hangzhou DAC Biotech Co., Ltd to initiate the   preclinical study   of the antibody-drug-conjugate (ADC)  DXC005, including the   pharmacology study ,   DMPK study   and the   safety evaluation . Medicilon has previously completed integrated  preclinical research  on ADC drugs cooperating with DAC Biotech and other companies. Two of them has been approved by NMPA and entered Phase I clinical trials. About Hangzhou DAC Biotech Co., Ltd Hangzhou DAC Biotech, Co., Ltd was officially registered in HEDA Area, Hangzhou City, Zhejiang Province, China around the end of Year 2012, and is located nearby the bank of beautiful Qiantang River. The company focuses on developing conjugate of monoclonal antibody and small molecular cytotoxic drug, both of which are banded together with smart linkers. About Antibody-Drug-Conjugate (ADC) ADCs ...

Medicilon assisted Hangzhou DAC Biotech in approval of clinical study of ADC drug DAC-002

  On July 20, 2020, DAC Biotech’s new   ADC drug development , TROP2-ADC—DAC-002 was approved of clinical study by NMPA. for the indication of solid malignant tumor. Medicilon completed   preclinical pharmacokinetic  and toxicological studies in this project, accelerating the development process. DAC-002 is an ADC anti-Trop2 monoclonal antibody conjugated by an intelligent ligand against Tubulysin B analogue. It is used to treat Trop2 triple negative breast cancer, small cell lung cancer, non-small cell lung cancer and pancreatic cancer.Trop2 can promote the proliferation, invasion, metastasis and diffusion of tumor cells, and its high expression is closely related to the shortening of survival time and poor prognosis of tumor patients. Therefore, it is of great significance to study anti-tumor drugs targeted by Trop2. Reference: Medicilon Assists - The first China-made targeting folic acid receptor FRα ADC injection BAT8006 was approved for clinical use Medicilon As...

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

  On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration.  The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages      Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies,  ADCs ,  mRNA vaccines ,  small nucleic acid drugs ,  PROTAC , and  CGT technical service platform  that have helped 421 INDs obtain clinical approval.  It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...